Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

被引：0
|
作者：
Uwe Reuter
Christian Lucas
David Dolezil
Austin L. Hand
Martha D. Port
Russell M. Nichols
Chad Stroud
Antje Tockhorn-Heidenreich
Holland C. Detke
机构：
[1] Charité Universitätsmedizin Berlin,
[2] Hôpital Salengro,undefined
[3] CHU de Lille,undefined
[4] DADO MEDICAL,undefined
[5] IQVIA,undefined
[6] Eli Lilly and Company,undefined
[7] Lilly Corporate Center,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
CGRP; Chronic migraine; Elderly; Episodic migraine; Galcanezumab; Migraine preventive; Monoclonal antibody; Treatment failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5465 / 5483
页数：18
相关论文
共 50 条
  • [1] Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial
    Reuter, Uwe
    Lucas, Christian
    Dolezil, David
    Hand, Austin L.
    Port, Martha D.
    Nichols, Russell M.
    Stroud, Chad
    Tockhorn-Heidenreich, Antje
    Detke, Holland C.
    ADVANCES IN THERAPY, 2021, 38 (11) : 5465 - 5483
  • [2] Galcanezumab in patients with treatment-resistant migraine: results from the open-label phase of the CONQUER phase 3 trial
    Detke, H. C.
    Reuter, U.
    Lucas, C.
    Dolezil, D.
    Hand, A.
    Tockhorn-Heidenreich, A.
    Stroud, C.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 298 - 298
  • [3] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Jiying Zhou
    Lianmei Zhong
    Debashish Chowdhury
    Kirill Skorobogatykh
    Guogang Luo
    Xiaosu Yang
    Mingjie Zhang
    Lingli Sun
    Hui Liu
    Chenxi Qian
    Shengyuan Yu
    The Journal of Headache and Pain, 24
  • [4] Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study
    Zhou, Jiying
    Zhong, Lianmei
    Chowdhury, Debashish
    Skorobogatykh, Kirill
    Luo, Guogang
    Yang, Xiaosu
    Zhang, Mingjie
    Sun, Lingli
    Liu, Hui
    Qian, Chenxi
    Yu, Shengyuan
    JOURNAL OF HEADACHE AND PAIN, 2023, 24 (01):
  • [5] Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures
    Schwedt, Todd J.
    Kuruppu, Dulanji K.
    Dong, Yan
    Standley, Katherine
    Yunes-Medina, Laura
    Pearlman, Eric
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
  • [6] Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures
    Todd J. Schwedt
    Dulanji K. Kuruppu
    Yan Dong
    Katherine Standley
    Laura Yunes-Medina
    Eric Pearlman
    The Journal of Headache and Pain, 2021, 22
  • [7] One-Year Treatment with Galcanezumab in Patients with Chronic Migraine: Results from the Open-Label Phase of the REGAIN Study
    Detke, Holland
    Pozo-Rosich, Patricia
    Reuter, Uwe
    Dolezil, David
    Li, Lily Q.
    Wang, Shufang
    Aurora, Sheena K.
    NEUROLOGY, 2019, 92 (15)
  • [8] ONE-YEAR TREATMENT WITH GALCANEZUMAB IN PATIENTS WITH CHRONIC MIGRAINE: RESULTS FROM THE OPEN-LABEL PHASE OF THE REGAIN STUDY
    Detke, H. C.
    Li, L. Q.
    Wang, S.
    Aurora, S. K.
    CEPHALALGIA, 2018, 38 : 149 - 149
  • [9] Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study
    Pozo-Rosich, Patricia
    Detke, Holland C.
    Wang, Shufang
    Dolezil, David
    Li, Lily Q.
    Aurora, Sheena K.
    Reuter, Uwe
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (05) : 731 - 742
  • [10] Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis
    Ailani, Jessica
    Andrews, Jeffrey Scott
    Tockhorn-Heidenreich, Antje
    Wenzel, Richard
    Rettiganti, Mallikarjuna
    ADVANCES IN THERAPY, 2022, 39 (10) : 4544 - 4555
12345